ABBV-319 elicits potent and durable antitumor activity in CDX models. (A-E) Growth of xenografted KARPAS422 (A), DB (B), RS4;11 (C-D), and OCI-LY19 (E) tumors after the indicated treatment regimen. Drug treatments were initiated within 24 hours after tumor size matching and randomization (A-C,E), whereas the large RS4;11 tumor (D) was dosed at day 43 after inoculation. Means ± SEM of tumor volumes were plotted for each treatment group vs days from randomization or days after inoculation. (F) Total antibody detected in mouse whole blood from the OCI-LY19 study (E). Means ± SEM are shown. (G) Volume of xenografted OCI-LY19 tumors after indicated treatment for 7 days. GRM was dosed at (QD × 5) × 3, whereas ABBV-319 was dosed as a SD. Means ± SEM of tumor volumes were plotted for each treatment group. (H) Quantitative reverse transcription polymerase chain reaction analysis of FKBP5, TSC22D3, and ZBTB16 expression in tumors after the indicated treatments. Means ± SEM of fold change relative to the vehicle control are displayed. QD, once daily; SD, single dose.